Research Paper on Long-Term Safety of High-Dose MSC Treatment Published in International Journal#Japan#Tokyo#MSC_Therapy#HELENE_BIO_Group#Omotesando_Helene_Clinic
Research Paper on Long-Term Safety of High-Dose MSC Treatment Published in International Journal
A new study from Omotesando Helene Clinic analyzes the long-term safety of high-dose MSC therapy, marking a significant contribution to regenerative medicine.
third-news.com
May 25, 2026 at 4:11 AM
Research Paper on Long-Term Safety of High-Dose MSC Treatment Published in International Journal#Japan#Tokyo#MSC_Therapy#HELENE_BIO_Group#Omotesando_Helene_Clinic
Projected Growth of MSC-Specific Cell Culture Medium Market to Reach $4.1 Billion by 2035#USA#New_York#regenerative_medicine#MSC_Therapy#Cell_Culture
Projected Growth of MSC-Specific Cell Culture Medium Market to Reach $4.1 Billion by 2035
The global MSC-specific cell culture medium market is set to surge ahead, reaching $4.1 billion by 2035, fueled by advancements in regenerative medicine and stem cell therapies.
third-news.com
September 4, 2025 at 4:46 PM
Projected Growth of MSC-Specific Cell Culture Medium Market to Reach $4.1 Billion by 2035#USA#New_York#regenerative_medicine#MSC_Therapy#Cell_Culture
Ending the Debate on MSCs: Catalyst for Practical MSC Therapy Implementation#China#Tianjin#MSC_Therapy#stem_cells#Mesenchymal_Stromal_Cells
Ending the Debate on MSCs: Catalyst for Practical MSC Therapy Implementation
After over two decades of debate, new research clarifies the practical application of mesenchymal stromal cells, shifting focus towards their therapeutic use.
third-news.com
February 27, 2025 at 5:02 AM
Ending the Debate on MSCs: Catalyst for Practical MSC Therapy Implementation#China#Tianjin#MSC_Therapy#stem_cells#Mesenchymal_Stromal_Cells
Debate on MSCs Concludes: Time to Implement MSC Therapy in Clinical Practice#China#Tianjin#regenerative_medicine#MSC_Therapy#mesenchymal_cells
Debate on MSCs Concludes: Time to Implement MSC Therapy in Clinical Practice
The long-standing debate on mesenchymal stromal cells versus stem cells is over. It's time to embrace MSC therapy in clinical applications effectively.
third-news.com
February 27, 2025 at 5:01 AM
Debate on MSCs Concludes: Time to Implement MSC Therapy in Clinical Practice#China#Tianjin#regenerative_medicine#MSC_Therapy#mesenchymal_cells
The End of the MSC Debate: A Call for Practical Implementation of MSC Therapy#USA#Tianjin#Medical_Research#MSC_Therapy#stem_cells
The End of the MSC Debate: A Call for Practical Implementation of MSC Therapy
The long-standing debate surrounding mesenchymal stem cells versus mesenchymal stromal cells is finally resolved, paving the way for clinical application of MSC therapy.
third-news.com
February 27, 2025 at 5:01 AM
The End of the MSC Debate: A Call for Practical Implementation of MSC Therapy#USA#Tianjin#Medical_Research#MSC_Therapy#stem_cells
Ending the Debate on MSCs: Time to Implement MSC Therapy in Clinical Settings#USA#Tianjin#regenerative_medicine#MSC_Therapy#Mesenchymal_Stromal_Cells
Ending the Debate on MSCs: Time to Implement MSC Therapy in Clinical Settings
The lengthy debate on mesenchymal stromal cells versus stem cells has concluded, paving the way for the practical application of MSC therapy in medicine.
third-news.com
February 27, 2025 at 5:01 AM
Ending the Debate on MSCs: Time to Implement MSC Therapy in Clinical Settings#USA#Tianjin#regenerative_medicine#MSC_Therapy#Mesenchymal_Stromal_Cells
FDA Makes History by Approving Ryoncil as First MSC Therapy for Pediatric Patients#United_States#FDA_Approval#Silver_Spring#Ryoncil#MSC_Therapy
FDA Makes History by Approving Ryoncil as First MSC Therapy for Pediatric Patients
The FDA has approved Ryoncil, the first-ever mesenchymal stromal cell therapy, designed specifically for children suffering from steroid-refractory acute graft-versus-host disease.
third-news.com
December 18, 2024 at 10:44 PM
FDA Makes History by Approving Ryoncil as First MSC Therapy for Pediatric Patients#United_States#FDA_Approval#Silver_Spring#Ryoncil#MSC_Therapy